메뉴 건너뛰기
Transplantation
Volumn 96, Issue 10, 2013, Pages
Successful long-term treatment of tma with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to mcp mutation
Author keywords

[No Author keywords available]
Indexed keywords

BASILIXIMAB; CYSTEINE; ECULIZUMAB; MEMBRANE COFACTOR PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; TRYPTOPHAN;
EID: 84891762496     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000435705.63428.1f     Document Type: Letter
Times cited : (9)
References (8)
  • 1
    • 84878589219 scopus 로고    scopus 로고
    • Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome
    • Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169
    • (2013) N Engl J Med , vol.368 , pp. 2169
    • Legendre, C.M.1    Licht, C.2    Muus, P.3
  • 2
    • 84870534251 scopus 로고    scopus 로고
    • Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation
    • Zuber J, Le QM, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; 12: 3337
    • (2012) Am J Transplant , vol.12 , pp. 3337
    • Zuber, J.1    Le, Q.M.2    Krid, S.3
  • 3
    • 84863724130 scopus 로고    scopus 로고
    • Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft
    • Alachkar N, Bagnasco SM, Montgomery RA. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transpl Int 2012; 25: e93.
    • (2012) Transpl Int , vol.25
    • Alachkar, N.1    Bagnasco, S.M.2    Montgomery, R.A.3
  • 4
    • 78650507665 scopus 로고    scopus 로고
    • Eculizumab: Safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolyticuremic syndrome: Case report
    • Chatelet V, Lobbedez T, Fremeaux-Bacchi V, et al. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolyticuremic syndrome: case report. Transplant Proc 2010; 42: 4353
    • (2010) Transplant Proc , vol.42 , pp. 4353
    • Chatelet, V.1    Lobbedez, T.2    Fremeaux-Bacchi, V.3
  • 5
    • 10744228553 scopus 로고    scopus 로고
    • Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
    • Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552
    • (2004) N Engl J Med , vol.350 , pp. 552
    • Hillmen, P.1    Hall, C.2    Marsh, J.C.3
  • 6
    • 70350130833 scopus 로고    scopus 로고
    • Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome
    • Chatelet V, Fremeaux-Bacchi V, Lobbedez T, et al. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009; 9: 2644.
    • (2009) Am J Transplant , vol.9 , pp. 2644
    • Chatelet, V.1    Fremeaux-Bacchi, V.2    Lobbedez, T.3
  • 7
    • 70350279315 scopus 로고    scopus 로고
    • Atypical hemolyticuremic syndrome
    • Noris M, Remuzzi G. Atypical hemolyticuremic syndrome. N Engl J Med 2009; 361: 1676
    • (2009) N Engl J Med , vol.361 , pp. 1676
    • Noris, M.1    Remuzzi, G.2
  • 8
    • 84867993256 scopus 로고    scopus 로고
    • Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
    • Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643
    • (2012) Nat Rev Nephrol , vol.8 , pp. 643
    • Zuber, J.1    Fakhouri, F.2    Roumenina, L.T.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.